Global /Canada /Healthcare /Biotechnology /ONC

Oncolytics Biotech Inc.

ONC

• TSX: ONC • Delayed

1.42CAD 2.2%

1.02 USD

As of 5 June 2026, Oncolytics Biotech Inc. has a market cap of $102.53M USD, ranking #25395 globally and #741 in Canada. It ranks #2278 in the Healthcare sector, and #437 in the Biotechnology industry.

Global Rank

25395

Country Rank

741

Sector Rank

2278

Industry Rank

437

Key Stats

Market Cap

$102.53MUSD

142.51M CAD

Enterprise Value

$92.65MUSD

128.77M CAD

EBITDA (TTM)

-$22.26MUSD

-30.94M CAD

Net Income (TTM)

-$21.88MUSD

-30.41M CAD

PB Ratio

23.4

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Biotechnology

CEO

Jared Kelly open_in_new

Employees

Founded

1998

Website

oncolyticsbiotech.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2.2%	-4.7%	-14%	145%	38%	6.8%	10%	-7.2%	-35%

News

Markets

Exchange	Ticker	Price	Quotes
Toronto Stock Exchange (TSX) MIC: XTSE PRIMARY	ONC Oncolytics Biotech Inc ISIN: CA6823108759 Shares Out.: Shares Outstanding: 100.361M¹ Shares Float: 98.088M² TV: TradingView: TSX: ONC SA: Stock Analysis: TSX: ONC YF: Yahoo Finance: ONC.TO GF: Google Finance: TSE: ONC BA: Barron's: ONC MS: Morningstar: XTSE: ONC	1.42 CAD	TV: TradingView: TSX: ONC SA: Stock Analysis: TSX: ONC YF: Yahoo Finance: ONC.TO GF: Google Finance: TSE: ONC BA: Barron's: ONC MS: Morningstar: XTSE: ONC
Cboe Canada (NEO) MIC: NEOE	ONC Oncolytics Biotech Inc ISIN: CA6823108759 TV: TradingView: NEO: ONC SA: Stock Analysis: NEO: ONC YF: Yahoo Finance: ONC.NE GF: Google Finance: NEO: ONC BA: Barron's: ONC MS: Morningstar: NEOE: ONC	1.41 CAD	TV: TradingView: NEO: ONC SA: Stock Analysis: NEO: ONC YF: Yahoo Finance: ONC.NE GF: Google Finance: NEO: ONC BA: Barron's: ONC MS: Morningstar: NEOE: ONC
NASDAQ MIC: XNAS	ONCY Oncolytics Biotech Inc ISIN: CA6823108759 TV: TradingView: NASDAQ: ONCY SA: Stock Analysis: NASDAQ: ONCY YF: Yahoo Finance: ONCY GF: Google Finance: NASDAQ: ONCY NQ: NASDAQ: ONCY BA: Barron's: ONCY MS: Morningstar: XNAS: ONCY	1.07 USD	TV: TradingView: NASDAQ: ONCY SA: Stock Analysis: NASDAQ: ONCY YF: Yahoo Finance: ONCY GF: Google Finance: NASDAQ: ONCY NQ: NASDAQ: ONCY BA: Barron's: ONCY MS: Morningstar: XNAS: ONCY

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Similar Companies

Industry: Biotechnology (Canada)

Name	Market Cap (USD) diff.	PE	Country
Aurinia Pharmaceuticals Inc. NASDAQ: AUPH	$1.99B 2K%	7.4	Canada
AbCellera Biologics Inc. NASDAQ: ABCL	$1.16B 1K%	-	Canada
Eupraxia Pharmaceuticals Inc. TSX: EPRX	$432.32M 600.89M CAD 322%	-	Canada
NervGen Pharma Corp. TSXV: NGEN	$295.12M 410.19M CAD 188%	-	Canada
Cybin Inc. NEO: CYBN	$254.07M 353.13M CAD 148%	-	Canada
Cardiol Therapeutics Inc. TSX: CRDL	$149.71M 208.08M CAD 46%	-	Canada

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 178K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 156K%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 47K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.36B 68.19T KRW 43K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.98B 60.27B AUD 42K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 41K%	37.2	Switzerland

chevron_leftBack